Pharma companies must balance R&D and acquisitions. Evaluate Pharma's analysis of the top 15 firms by 2023 sales reveals spending trends.| Evaluate
Obesity drugs will dominate 2030 forecasts, with new technologies and strong pharma acquisitions boosting biotech growth.| Evaluate